X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Kodiak Sciences has concluded recruitment in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. Over 550 patients enrolled worldwide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TP-03
Therapeutic Area: Ophthalmology Product Name: TP-03
Highest Development Status: Phase II/ Phase III Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
The company announced compelling results from its Phase 2a Mars and Phase 2b Jupiter trials for TP-03. In both trials it was observed that the use of TP-03 for 4 weeks was well-tolerated and showed compelling efficacy in the treatment of Demodex blepharitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
New data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
